Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Moxifloxacin hydrochloride
A A H Pharmaceuticals Ltd
J01MA14
Moxifloxacin hydrochloride
400mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05011200; GTIN: 5025903016991
Package leaflet: Information for the patient Moxifloxacin 400 mg film coated tablets For adults Moxifloxacin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet What Moxifloxacin is and what it is used for What you need to know before you take Moxifloxacin How to take Moxifloxacin Possible side effects How to store Moxifloxacin Contents of the pack and other information What Moxifloxacin is and what it is used for This medicine contains the active substance moxifloxacin, which belongs to a group of antibiotics called fluoroquinolones. Moxifloxacin works by killing bacteria that cause infections. Moxifloxacin is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which moxifloxacin is active. Moxifloxacin should only be used to treat these infections when usual antibiotics cannot be used or have not worked: Infection of the sinuses, sudden worsening of long term inflammation of the airways or infection of the lungs (pneumonia) acquired outside the hospital (except severe cases). Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections of the uterus mucous membrane. Moxifloxacin tablets are not sufficient on their own for treating this kind of infection. Therefore, another antibiotic in addition to Moxifloxacin tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section 2 What you need to Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Moxifloxacin 400 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg moxifloxacin, corresponding to 436.37 mg moxifloxacin hydrochloride. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Pink oblong biconvex film coated tablets with dimensions 19.4 x 7.8 mm in diameter and 5.8 mm in thickness 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Moxifloxacin 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed: - Acute bacterial sinusitis (adequately diagnosed) In acute bacterial sinusitis Moxifloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. - Acute exacerbation of chronic obstructive pulmonary disease including bronchitis (adequately diagnosed) _ _ In acute exacerbation of chronic obstructive pulmonary disease including bronchitis Moxifloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. - Community acquired pneumonia, except severe cases - Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess. Moxifloxacin 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxi Read the complete document